A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Protocol No
CTN-1703-1801
Principal Investigator
Lyndsey Runaas
Phase
III
Summary
This study is being done to see whether one combination of medications designed to prevent (GVHD) is better than another. The purpose of the companion study is to understand if the bacteria and proteins in your gut and body fluids can help the doctors predict transplant outcomes
Description
TAC/MTX vs.TAC/MMF/PTCY for prevention of GVHD and Micobiome and immune Reconsitution
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: